Alembic Pharmaceuticals Limited has announced a scheduled one-on-one investor meeting with Nomura Holdings, demonstrating the company's commitment to maintaining regular dialogue with institutional investors and stakeholders.

Meeting Details

The pharmaceutical company has provided specific details about the upcoming investor engagement:

Regulatory Compliance

The company has fulfilled its regulatory obligations by notifying both major stock exchanges about this investor meeting. The intimation was filed on March 20, 2026, under Regulation 30, which governs disclosure requirements for listed companies.

The notification was simultaneously sent to:

• BSE Limited (Scrip Code: 533573)
• National Stock Exchange of India Ltd. (Symbol: APLLTD)

Corporate Communication

Company Secretary Manisha Saraf signed the official communication, ensuring proper authorization and documentation of the investor engagement activity. The digital signature was applied on March 20, 2026, at 11:36:25 IST, providing a clear audit trail for the regulatory filing.

Such investor meetings are part of standard corporate practices, allowing institutional investors to engage directly with company management and gain insights into business operations, strategic direction, and financial performance. The video conferencing format reflects modern communication practices while maintaining effective investor relations.

Alembic Pharmaceuticals has officially incorporated a new subsidiary named Alembic Pharmaceuticals (Thailand) Co., Ltd in Thailand, as disclosed in its regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This strategic expansion represents the company's continued efforts to strengthen its global footprint in key Southeast Asian markets.

Financial Structure and Shareholding

The newly incorporated subsidiary has been established with specific financial parameters:

Strategic Business Objectives

According to the regulatory disclosure, the primary objective of establishing this subsidiary is to explore new business opportunities in the Thai geography. The company aims to promote, sell and distribute pharmaceutical products through this new entity, positioning Thailand as a strategic hub for regional operations.

Regulatory Compliance

The incorporation was formally communicated to both BSE Limited (Scrip Code: 533573) and National Stock Exchange of India Ltd (NSE Symbol: APLLTD) through proper regulatory channels. Company Secretary Manisha Saraf signed the disclosure documents, ensuring full compliance with listing obligations.

Market Expansion Strategy

This subsidiary establishment demonstrates Alembic Pharmaceuticals' proactive approach to international market development. Thailand represents a significant pharmaceutical market opportunity in Southeast Asia, offering potential for growth and enhanced competitive positioning in the global pharmaceutical landscape. The move aligns with the company's broader international expansion strategy to strengthen its presence in emerging markets.